Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

RINVOQ 15 mg prolonged-release tablets

Active Ingredient:
upadacitinib hemihydrate
Company:  
AbbVie Ltd See contact details
ATC code: 
L04AF03
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials Letters to HCPs
{arrow_left}
{arrow_right}

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

{pdf_link}

RINVOQ HCP Guide

{healthcare_pro_orange} For Healthcare Professionals

HCP educational guide- Safety information to consider when prescribing Upadacitinib.

{pdf_link}

RINVOQ Patient Card

Patient Card- Safety information about Rinvoq (Upadacitinib) for patients

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

AbbVie Ltd
Company image
Address
AbbVie House, Vanwall Business Park, Vanwall Road, Maidenhead, Berkshire, SL6 4UB, UK
Telephone
+44 (0)1628 561 090
Medical Information e-mail
[email protected]
WWW
www.abbvie.co.uk
WWW
www.abbviemedinfo.com
Stock Availability
(HCP's only) [email protected]
Medical Information Direct Line
+44 (0)1628 561 092